Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mantle cell lymphoma, drawn from the whole corpus: 48 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
TP53-mutant and blastoid MCL fail chemo-immunotherapy; need CAR-T or bispecific-based first-line trials.
MRD-guided treatment duration.
Background: Minimal / molecular residual disease (MRD). Also on OnCo: Treatment journeys · Survivorship planner.
Whether CAR-T should precede pirtobrutinib or follow it.
Cost and access of indefinite BTK-inhibitor therapy.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
TRIANGLE showed that adding ibrutinib to induction and maintenance improves failure-free survival and that transplant is not superior to an ibrutinib-containing regimen without it, but it did not answer which of the three arms is best for a given patient, and the arm that omits transplant has the shortest follow-up.
TP53-mutated mantle cell lymphoma responds poorly to every intensive chemotherapy strategy tested, including autologous transplant, and there is no regimen with randomised evidence in this group.
ENRICH showed ibrutinib-rituximab beats R-CHOP in older patients but not bendamustine-rituximab, so the right first treatment for an older patient depends on which comparator a clinician would otherwise have chosen, which is an uncomfortable basis for a recommendation.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 24 changes by month →When this page itself was last checked or edited.
Relapsed/refractory mantle cell lymphoma after ≥2 lines including a BTK inhibitor (accelerated)
A milestone in how this cancer is treated.
Median progression-free survival 66.
Progression-free survival adjusted hazard ratio 0.
Median progression-free survival 31.